RNA-focused Remix Therapeutics agreed on a strategic small-molecule discovery and development collaboration with Janssen Pharmaceutica N.V., a division of Johnson & Johnson.
Emergent BioSolutions came into 2022 after a challenging year that saw the company lose a lucrative contract with the U.S. government following a production mishap that ruined millions of doses of Johnson & Johnson’s COVID-19 vaccine.
The United States signed contracts worth about $1 billion for doses of the antibody-based Covid-19 treatment from Britain’s GSK and U.S.-based Vir Biotechnology, as countries seek to secure promising options beyond vaccines.
Britain’s GSK and partner Vir Biotechnology said on November 12 their antibody-based Covid-19 drug was shown in a trial to work as well when given as a shot in the arm as when administered via the standard infusion, potentially offering more convenience.
As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.
